|
BIIB's Operating Income Growth by Quarter and Year
Biogen Inc 's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| BIIB Operating Income (in millions $) |
FY 2020 |
FY 2019 |
FY 2018 |
FY 2017 |
| IV Quarter |
December |
-330.70
|
1,777.70
|
1,443.10
|
1,465.80
|
| III Quarter |
September |
1,086.40
|
1,806.30
|
1,697.60
|
1,653.50
|
| II Quarter |
June |
1,974.50
|
1,955.90
|
1,213.20
|
1,200.60
|
| I Quarter |
March |
1,819.90
|
1,502.70
|
1,534.70
|
1,024.30
|
| FY |
|
4,550.10
|
7,042.60
|
5,888.60
|
5,344.20
|
| BIIB Operating Income forth quarter 2020 Y/Y Growth Comment |
Biogen Inc in the forth quarter recorded Operating Loss of $ -330.70 millions.
Among companies who have reported forth quarter results in the Biotechnology & Drugs industry only one Company has achieved higher year on year Operating Income results in the forth quarter. While Biogen Inc ' s Operating Income no change of % ranks overall at the positon no. 179 in the forth quarter.
Explain Operating Income growth
|
| BIIB Operating Income ( Y/Y Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
- |
23.19 % |
-1.55 % |
65.4 % |
| III Quarter |
September |
-39.85 % |
6.4 % |
2.67 % |
16.01 % |
| II Quarter |
June |
0.95 % |
61.22 % |
1.05 % |
-17.8 % |
| I Quarter |
March |
21.11 % |
-2.09 % |
49.83 % |
-25.69 % |
| FY |
|
-35.39 % |
19.6 % |
10.19 % |
3.76 % |
BIIB Operating Income (Quarter on Quarter Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
- |
-1.58 % |
-14.99 % |
-11.35 % |
| III Quarter |
September |
-44.98 % |
-7.65 % |
39.93 % |
37.72 % |
| II Quarter |
June |
8.49 % |
30.16 % |
-20.95 % |
17.21 % |
| I Quarter |
March |
2.37 % |
4.13 % |
4.7 % |
15.58 % |
| FY (Year on Year) |
|
-35.39 % |
19.6 % |
10.19 % |
3.76 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 106.48 % |
6.52 % |
-50.43 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 106.48 % |
6.52 % |
-50.43 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
| Operating Income by Quarter for the Fiscal Years 2017, 2018, 2019, 2020 |
Biogen Inc 's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| BIIB's IV. Quarter Q/Q Operating Income Comment |
IV. Quarter 2020 Operating Loss of -330.70 millions by Biogen Inc appear even worse if you take a look at 1,086.40 millions in the third quarter.
Within Biotechnology & Drugs industry Biogen Inc achieved highest sequential Operating Income growth. While Biogen Inc 's Operating Income growth quarter on quarter, overall rank is . |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| BIIB's IV. Quarter Q/Q Operating Income Comment |
Recent accomplishment of -330.70 millions by Biogen Inc look even more unfavourable compare to the 1,086.40 millions a quarter before.
Within Biotechnology & Drugs industry Biogen Inc achieved highest sequential Operating Income growth. While Biogen Inc 's Operating Income growth quarter on quarter, overall rank is . |
|
Biogen Inc 's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Dec 31 2020) |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
12 Months Ending
(Dec 31 2019) |
| Cumulative Operating Income 12 Months Ending |
$ 4,550.10 |
$ 6,658.50 |
$ 7,378.40 |
$ 7,359.80 |
$ 7,042.60 |
| Y / Y Operating Income Growth (TTM) |
-35.39 % |
-0.74 % |
11.81 % |
25.67 % |
19.6 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 146 |
# 912 |
# 663 |
# 626 |
# 101 |
| Seqeuential Operating Income Change (TTM) |
-31.66 % |
-9.76 % |
0.25 % |
4.5 % |
4.99 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 1107 |
# 1662 |
# 946 |
# 611 |
# 304 |
| Cumulative Operating Income growth
Comment |
Biogen Inc 's cumulative 12 months Operating Income continue to drop, but on the faster rate at -35.39% year on year, at Dec 31 2020 compare to the -0.74% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Operating Income would be $4,550 millions.
Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 146, from total ranking in previous quarter at 912. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
106.48 % |
6.52 % |
-50.43 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
443.68 % |
37.96 % |
-35.39 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 15 |
| Sector |
# 96 |
| S&P 500 |
# 1107 |
|
| Cumulative Operating Income growth
Comment |
Biogen Inc 's cumulative 12 months Operating Income continue to drop, but on the faster rate at -35.39% year on year, at Dec 31 2020 compare to the -0.74% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Operating Income would be $4,550 millions.
Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 146, from total ranking in previous quarter at 912. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
106.48 % |
6.52 % |
-50.43 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
443.68 % |
37.96 % |
-35.39 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 15 |
| Sector |
# 96 |
| S&P 500 |
# 1107 |
|
